+357 96 030922
info@marketpublishers.com

Global Long-Acting HIV PrEP Supply, Demand and Key Producers, 2026-2032

https://marketpublishers.com/r/G381B4199C24EN.html
Date: September 2026
Pages: 76
Price: US$ 4,480.00 (Single User License)
ID: G381B4199C24EN

Abstracts

The global Long-Acting HIV PrEP market size is expected to reach $ 12214 million by 2032, rising at a market growth of 36.6% CAGR during the forecast period (2026-2032).

Long-Acting HIV PrEP refers to long-duration antiretroviral pre-exposure prophylaxis delivered through scheduled injectable formulations to reduce the risk of sexually acquired HIV-1 infection in HIV-negative individuals. This study focuses on commercially established long-acting injectable PrEP based on cabotegravir and lenacapavir, covering intramuscular and subcutaneous administration, dosing schedules ranging from every two months to every six months, and the corresponding integrase strand transfer inhibitor and HIV-1 capsid inhibitor mechanisms. These products are administered through professional healthcare settings and require confirmation of HIV-negative status before initiation and appropriate testing during continued use. The principal downstream settings include hospitals and HIV specialty clinics, sexual health clinics, community health centers and public-health PrEP programs. Compared with daily oral prevention, the defining commercial attribute of Long-Acting HIV PrEP is the extension of effective drug exposure across substantially longer dosing intervals, creating a differentiated prevention option for users seeking lower dosing frequency and for healthcare systems aiming to improve persistence with PrEP programs.

Key Findings

The average gross profit margin of this product is 90%

Commercial Long-Acting HIV PrEP now spans two distinct injectable mechanisms

+357 96 030922
info@marketpublishers.com

Current dosing intervals range from every two to every six months

Cabotegravir holds an earlier commercial position in long-acting injectable PrEP

Lenacapavir extends injectable HIV prevention to a twice-yearly dosing schedule

Scheduled HIV testing remains integral to long-acting injectable PrEP delivery

Market Trends

The Long-Acting HIV PrEP market is transitioning from a single long-acting injectable concept toward a differentiated platform defined by dosing duration, administration route and mechanism of action. Cabotegravir established the every-two-month intramuscular model, while lenacapavir has extended the interval to twice-yearly subcutaneous administration, materially changing the competitive benchmark for dosing convenience. The longer-term direction of the market is therefore shifting from simply replacing daily tablets toward reducing the number of prevention-related dosing events while preserving reliable clinical follow-up. At the same time, product innovation is increasingly being linked with simplified HIV testing, differentiated service delivery and integration into broader sexual-health and public-health programs. WHO recommendations covering both long-acting cabotegravir and lenacapavir reinforce the development of a multi-option PrEP environment in which long-acting injectables are positioned alongside other prevention choices rather than as a uniform replacement for all existing PrEP approaches.

Market Dynamics

Drivers

Demand for Long-Acting HIV PrEP is primarily supported by the persistent challenge of maintaining adherence to frequently dosed prevention regimens and by growing emphasis on expanding user choice within HIV prevention. Injectable products reduce the number of medication-taking events required over a year and may be particularly relevant for users who experience difficulties with daily pill adherence, privacy concerns or stigma associated with storing and taking oral medication. Regulatory approvals and inclusion of long-acting injectable options in international HIV prevention

+357 96 030922
info@marketpublishers.com

recommendations have also strengthened the clinical foundation for broader implementation. In parallel, governments and public-health organizations increasingly view diversified PrEP options as a means of improving effective prevention coverage rather than relying on a single delivery model.

Restraints

The main restraints arise from the more structured service requirements associated with injectable PrEP. Unlike self-administered daily oral medication, current long-acting injections generally require healthcare-provider administration, scheduled return visits and HIV testing before initiation and during continued use. Missed or significantly delayed dosing may complicate preventive management, while use in individuals with undiagnosed HIV infection can create drug-resistance concerns. These operational requirements increase dependence on clinic capacity, patient tracking, reimbursement and reliable appointment systems. Consequently, the commercial advantage of lower dosing frequency does not automatically translate into easier healthcare delivery, particularly in markets where HIV testing infrastructure, trained providers or financing for preventive services remains limited.

Opportunities

The principal opportunity lies in expanding PrEP participation among populations that have not been effectively retained by conventional prevention delivery models. Longer dosing intervals create potential for more differentiated service models linking HIV specialty care, sexual-health clinics, community health centers and public-health programs. Simplified testing approaches may further support decentralization of long-acting PrEP services and reduce operational barriers to initiation and continuation. The twice-yearly dosing model also provides a new reference point for future product development, potentially shifting competitive differentiation toward duration of protection, ease of administration and service efficiency. Markets with substantial unmet HIV prevention needs represent an important long-term opportunity, although realization of this potential will depend heavily on national guidelines, procurement mechanisms, reimbursement and access programs.

Challenges

Long-Acting HIV PrEP creates new implementation challenges alongside its adherence

+357 96 030922
info@marketpublishers.com

advantages. Healthcare systems must maintain accurate HIV-negative confirmation, injection scheduling and follow-up over extended intervals, while providers must manage individuals who miss injections or discontinue treatment. The prolonged pharmacologic activity that supports long dosing intervals also makes resistance management and testing strategy particularly important if HIV infection occurs during periods of declining drug concentration. At the market level, differences in regulatory approval, reimbursement, public-health funding and provider readiness can produce substantial variation in adoption between countries. Manufacturers therefore face the dual task of demonstrating strong prevention performance while building scalable delivery systems that translate clinical efficacy into consistent real-world uptake.

Industry Chain Analysis

The Long-Acting HIV PrEP industry chain begins with antiretroviral active pharmaceutical ingredients, pharmaceutical excipients, formulation materials and sterile injectable manufacturing inputs. The middle of the chain encompasses long-acting formulation development, sterile production and fill-finish, quality control, clinical development, regulatory registration, packaging and product supply. Compared with conventional solid-dose medicines, the technical value of the product is concentrated not only in the active ingredient but also in achieving controlled and persistent drug exposure over extended periods through specialized injectable formulations. This makes formulation technology, clinical evidence, intellectual property and regulatory capability major components of product value.

Downstream value is realized through hospitals, HIV specialty clinics, sexual-health services, community healthcare facilities and public-health PrEP programs. Because the products require HIV testing and professionally managed dosing schedules, manufacturers depend more heavily on healthcare-delivery infrastructure than suppliers of self-administered preventive medicines. Commercial performance is therefore influenced not only by pharmaceutical production costs but also by reimbursement, procurement, clinical workflow integration, patient identification and long-term retention. As dosing frequency decreases, the industry chain is likely to place greater emphasis on reliable patient recall systems and coordinated prevention services rather than prescription volume alone.

Segment Insights

+357 96 030922
info@marketpublishers.com

The current Long-Acting HIV PrEP market is structured around two differentiated pharmacological segments. Cabotegravir Long-Acting PrEP is an integrase strand transfer inhibitor delivered through intramuscular injection, with maintenance dosing every two months after initiation. Its earlier regulatory commercialization gives it a comparatively established position in injectable PrEP service models. Lenacapavir Long-Acting PrEP represents the newer HIV-1 capsid inhibitor segment and uses subcutaneous administration with maintenance dosing every six months, introducing a substantially longer injection interval and a differentiated mechanism of action.

From a product-structure perspective, competition is therefore moving beyond basic injectable versus oral differentiation. Intramuscular and subcutaneous administration, two-month and six-month intervals, and INSTI versus capsid-inhibitor mechanisms form distinct commercial positioning dimensions. Cabotegravir benefits from an earlier market-entry profile and accumulated implementation experience, while lenacapavir raises the benchmark for dosing duration. The relative development of these segments will increasingly depend on patient preference, provider workflow, reimbursement, persistence with scheduled visits and the ability of prevention programs to integrate each dosing model efficiently.

Downstream Market Opportunities

Downstream demand for Long-Acting HIV PrEP is concentrated in professionally managed HIV prevention settings rather than conventional retail drug channels. HIV specialty clinics and sexual-health clinics are natural early-adoption environments because testing, risk assessment, counseling and injection administration can be integrated within established workflows. Community health centers and public-health PrEP programs represent a broader expansion opportunity as testing and preventive services become more decentralized. The commercial opportunity is particularly significant where providers can identify individuals with substantial HIV exposure risk but low persistence with frequently dosed prevention. Future market expansion will therefore depend on converting long dosing intervals into practical improvements in retention, convenience and continuity of prevention services rather than relying solely on pharmacological differentiation.

Regional Insights

North America currently represents the most mature commercialization environment

+357 96 030922
info@marketpublishers.com

within the Long-Acting HIV PrEP market, reflecting earlier regulatory introduction of cabotegravir and subsequent launch of twice-yearly lenacapavir in the United States. Europe has also developed a broader long-acting PrEP portfolio following regulatory authorization of cabotegravir and later lenacapavir, providing a second major regulated market for competing long-duration injection strategies. These markets benefit from comparatively established HIV testing networks, specialty care infrastructure and reimbursement mechanisms, although access can still vary by healthcare system.

In other regions, market development is more closely tied to national HIV prevention policies, public procurement, donor-supported programs, regulatory timelines and healthcare-delivery capacity. WHO recommendations for both cabotegravir and lenacapavir create an important policy foundation for broader adoption, particularly in markets with high unmet prevention needs. However, commercial maturity is likely to remain uneven because clinical availability does not automatically translate into funded and scalable access. For manufacturers, regional expansion will increasingly require differentiated pricing, public-health partnerships and service-delivery models adapted to local testing and follow-up capacity.

Competitive Landscape Analysis

The confirmed commercial landscape of Long-Acting HIV PrEP is highly concentrated around ViiV Healthcare and Gilead Sciences, but their competitive positioning is differentiated rather than directly homogeneous. ViiV Healthcare established the earlier long-acting injectable PrEP model through cabotegravir, building its position around an intramuscular regimen with maintenance injections every two months. Gilead Sciences subsequently entered the market with lenacapavir and differentiated its offering through a novel HIV-1 capsid mechanism and twice-yearly subcutaneous dosing. As a result, competition is increasingly centered on dosing interval, route of administration, implementation convenience, clinical confidence and access rather than price alone. ViiV's earlier commercialization supports accumulated provider familiarity, whereas Gilead's six-month dosing interval creates a strong product-level differentiation point. Future competitive outcomes will depend on how effectively each company converts these pharmacological and dosing characteristics into sustained patient uptake, reimbursement coverage and integration into national and community-based HIV prevention programs.

Report Scope

+357 96 030922
info@marketpublishers.com

This report studies the global Long-Acting HIV PrEP demand, key companies, and key regions.

This report is a detailed and comprehensive analysis of the world market for Long-Acting HIV PrEP, and provides market size (US$ million) and Year-over-Year (YoY) growth, considering 2025 as the base year. This report explores demand trends and competition, as well as details the characteristics of Long-Acting HIV PrEP that contribute to its increasing demand across many markets.

Highlights and key features of the study

Global Long-Acting HIV PrEP total market, 2021-2032, (USD Million)

Global Long-Acting HIV PrEP total market by region & country, CAGR, 2021-2032, (USD Million)

U.S. VS China: Long-Acting HIV PrEP total market, key domestic companies, and share, (USD Million)

Global Long-Acting HIV PrEP revenue by player, revenue and market share 2021-2026, (USD Million)

Global Long-Acting HIV PrEP total market by Type, CAGR, 2021-2032, (USD Million)

Global Long-Acting HIV PrEP total market by Application, CAGR, 2021-2032, (USD Million)

This report profiles major players in the global Long-Acting HIV PrEP market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Gilead Sciences, GSK, etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.

Stakeholders would have ease in decision-making through various strategy matrices

+357 96 030922
info@marketpublishers.com

used in analyzing the world Long-Acting HIV PrEP market

Detailed Segmentation:

Each section contains quantitative market data including market by value (US$ Millions), by player, by regions, by Type, and by Application. Data is given for the years 2021-2032 by year with 2025 as the base year, 2026 as the estimate year, and 2027-2032 as the forecast year.

Global Long-Acting HIV PrEP Market, By Region:

United States

China

Europe

Japan

South Korea

ASEAN

India

Rest of World

Market Segmentation

Global Long-Acting HIV PrEP Market, Segmentation by Type:

Cabotegravir Long-Acting PrEP

Lenacapavir Long-Acting PrEP

+357 96 030922
info@marketpublishers.com

Global Long-Acting HIV PrEP Market, Segmentation by Route of Administration:

Intramuscular Injectable PrEP

Subcutaneous Injectable PrEP

Global Long-Acting HIV PrEP Market, Segmentation by Time of Administration:

Every 2 Months

Every 6 Months

Global Long-Acting HIV PrEP Market, Segmentation by Application:

Hospitals and HIV Specialty Clinics

Sexual Health Clinics

Public Health PrEP Programs

Companies Profiled:

Gilead Sciences

GSK

Key Questions Answered

1. How big is the global Long-Acting HIV PrEP market?
2. What is the demand of the global Long-Acting HIV PrEP market?
3. What is the year over year growth of the global Long-Acting HIV PrEP market?

+357 96 030922
info@marketpublishers.com

4. What is the total value of the global Long-Acting HIV PrEP market?
5. Who are the Major Players in the global Long-Acting HIV PrEP market?
6. What are the growth factors driving the market demand?

+357 96 030922
info@marketpublishers.com

Contents

1 SUPPLY SUMMARY

1.1 Long-Acting HIV PrEP Introduction
1.2 World Long-Acting HIV PrEP Market Size & Forecast (2021 & 2025 & 2032)
1.3 World Long-Acting HIV PrEP Total Market by Region (by Headquarter Location)
  1.3.1 World Long-Acting HIV PrEP Market Size by Region (2021-2032), (by Headquarter Location)
  1.3.2 United States Based Company Long-Acting HIV PrEP Revenue (2021-2032)
  1.3.3 China Based Company Long-Acting HIV PrEP Revenue (2021-2032)
  1.3.4 Europe Based Company Long-Acting HIV PrEP Revenue (2021-2032)
  1.3.5 Japan Based Company Long-Acting HIV PrEP Revenue (2021-2032)
  1.3.6 South Korea Based Company Long-Acting HIV PrEP Revenue (2021-2032)
  1.3.7 ASEAN Based Company Long-Acting HIV PrEP Revenue (2021-2032)
  1.3.8 India Based Company Long-Acting HIV PrEP Revenue (2021-2032)
1.4 Market Drivers, Restraints and Trends
  1.4.1 Long-Acting HIV PrEP Market Drivers
  1.4.2 Factors Affecting Demand
  1.4.3 Major Market Trends

2 DEMAND SUMMARY

2.1 World Long-Acting HIV PrEP Consumption Value (2021-2032)
2.2 World Long-Acting HIV PrEP Consumption Value by Region
  2.2.1 World Long-Acting HIV PrEP Consumption Value by Region (2021-2026)
  2.2.2 World Long-Acting HIV PrEP Consumption Value Forecast by Region (2027-2032)
2.3 United States Long-Acting HIV PrEP Consumption Value (2021-2032)
2.4 China Long-Acting HIV PrEP Consumption Value (2021-2032)
2.5 Europe Long-Acting HIV PrEP Consumption Value (2021-2032)
2.6 Japan Long-Acting HIV PrEP Consumption Value (2021-2032)
2.7 South Korea Long-Acting HIV PrEP Consumption Value (2021-2032)
2.8 ASEAN Long-Acting HIV PrEP Consumption Value (2021-2032)
2.9 India Long-Acting HIV PrEP Consumption Value (2021-2032)

3 WORLD LONG-ACTING HIV PREP COMPANIES COMPETITIVE ANALYSIS

3.1 World Long-Acting HIV PrEP Revenue by Player (2021-2026)

+357 96 030922
info@marketpublishers.com

3.2 Industry Rank and Concentration Rate (CR)
3.2.1 Global Long-Acting HIV PrEP Industry Rank of Major Players
3.2.2 Global Concentration Ratios (CR4) for Long-Acting HIV PrEP in 2025
3.2.3 Global Concentration Ratios (CR8) for Long-Acting HIV PrEP in 2025
3.3 Long-Acting HIV PrEP Company Evaluation Quadrant
3.4 Long-Acting HIV PrEP Market: Overall Company Footprint Analysis
3.4.1 Long-Acting HIV PrEP Market: Region Footprint
3.4.2 Long-Acting HIV PrEP Market: Company Product Type Footprint
3.4.3 Long-Acting HIV PrEP Market: Company Product Application Footprint
3.5 Competitive Environment
3.5.1 Historical Structure of the Industry
3.5.2 Barriers of Market Entry
3.5.3 Factors of Competition
3.6 Mergers & Acquisitions Activity

4 UNITED STATES VS CHINA VS REST OF WORLD (BY HEADQUARTER LOCATION)

4.1 United States VS China: Long-Acting HIV PrEP Revenue Comparison (by Headquarter Location)
4.1.1 United States VS China: Long-Acting HIV PrEP Revenue Comparison (2021 & 2025 & 2032) (by Headquarter Location)
4.1.2 United States VS China: Long-Acting HIV PrEP Revenue Market Share Comparison (2021 & 2025 & 2032)
4.2 United States Based Companies VS China Based Companies: Long-Acting HIV PrEP Consumption Value Comparison
4.2.1 United States VS China: Long-Acting HIV PrEP Consumption Value Comparison (2021 & 2025 & 2032)
4.2.2 United States VS China: Long-Acting HIV PrEP Consumption Value Market Share Comparison (2021 & 2025 & 2032)
4.3 United States Based Long-Acting HIV PrEP Companies and Market Share, 2021-2026
4.3.1 United States Based Long-Acting HIV PrEP Companies, Headquarters (States, Country)
4.3.2 United States Based Companies Long-Acting HIV PrEP Revenue, (2021-2026)
4.4 China Based Companies Long-Acting HIV PrEP Revenue and Market Share, 2021-2026
4.4.1 China Based Long-Acting HIV PrEP Companies, Company Headquarters (Province, Country)

+357 96 030922
info@marketpublishers.com

4.4.2 China Based Companies Long-Acting HIV PrEP Revenue, (2021-2026)
4.5 Rest of World Based Long-Acting HIV PrEP Companies and Market Share, 2021-2026
4.5.1 Rest of World Based Long-Acting HIV PrEP Companies, Headquarters (Province, Country)
4.5.2 Rest of World Based Companies Long-Acting HIV PrEP Revenue (2021-2026)

5 MARKET ANALYSIS BY TYPE

5.1 World Long-Acting HIV PrEP Market Size Overview by Type: 2021 VS 2025 VS 2032
5.2 Segment Introduction by Type
5.2.1 Cabotegravir Long-Acting PrEP
5.2.2 Lenacapavir Long-Acting PrEP
5.3 Market Segment by Type
5.3.1 World Long-Acting HIV PrEP Market Size by Type (2021-2026)
5.3.2 World Long-Acting HIV PrEP Market Size by Type (2027-2032)
5.3.3 World Long-Acting HIV PrEP Market Size Market Share by Type (2027-2032)

6 MARKET ANALYSIS BY ROUTE OF ADMINISTRATION

6.1 World Long-Acting HIV PrEP Market Size Overview by Route of Administration: 2021 VS 2025 VS 2032
6.2 Segment Introduction by Route of Administration
6.2.1 Intramuscular Injectable PrEP
6.2.2 Subcutaneous Injectable PrEP
6.3 Market Segment by Route of Administration
6.3.1 World Long-Acting HIV PrEP Market Size by Route of Administration (2021-2026)
6.3.2 World Long-Acting HIV PrEP Market Size by Route of Administration (2027-2032)
6.3.3 World Long-Acting HIV PrEP Market Size Market Share by Route of Administration (2027-2032)

7 MARKET ANALYSIS BY TIME OF ADMINISTRATION

7.1 World Long-Acting HIV PrEP Market Size Overview by Time of Administration: 2021 VS 2025 VS 2032
7.2 Segment Introduction by Time of Administration

+357 96 030922
info@marketpublishers.com

7.2.1 Every 2 Months
7.2.2 Every 6 Months
7.3 Market Segment by Time of Administration
7.3.1 World Long-Acting HIV PrEP Market Size by Time of Administration (2021-2026)
7.3.2 World Long-Acting HIV PrEP Market Size by Time of Administration (2027-2032)
7.3.3 World Long-Acting HIV PrEP Market Size Market Share by Time of Administration (2027-2032)

8 MARKET ANALYSIS BY APPLICATION

8.1 World Long-Acting HIV PrEP Market Size Overview by Application: 2021 VS 2025 VS 2032
8.2 Segment Introduction by Application
8.2.1 Hospitals and HIV Specialty Clinics
8.2.2 Sexual Health Clinics
8.2.3 Public Health PrEP Programs
8.3 Market Segment by Application
8.3.1 World Long-Acting HIV PrEP Market Size by Application (2021-2026)
8.3.2 World Long-Acting HIV PrEP Market Size by Application (2027-2032)
8.3.3 World Long-Acting HIV PrEP Market Size Market Share by Application (2021-2032)

9 COMPANY PROFILES

9.1 Gilead Sciences
9.1.1 Gilead Sciences Details
9.1.2 Gilead Sciences Major Business
9.1.3 Gilead Sciences Long-Acting HIV PrEP Product and Services
9.1.4 Gilead Sciences Long-Acting HIV PrEP Revenue, Gross Margin and Market Share (2021-2026)
9.1.5 Gilead Sciences Recent Developments/Updates
9.1.6 Gilead Sciences Competitive Strengths & Weaknesses
9.2 GSK
9.2.1 GSK Details
9.2.2 GSK Major Business
9.2.3 GSK Long-Acting HIV PrEP Product and Services
9.2.4 GSK Long-Acting HIV PrEP Revenue, Gross Margin and Market Share (2021-2026)
9.2.5 GSK Recent Developments/Updates

+357 96 030922
info@marketpublishers.com

9.2.6 GSK Competitive Strengths & Weaknesses

10 INDUSTRY CHAIN ANALYSIS

10.1 Long-Acting HIV PrEP Industry Chain
10.2 Long-Acting HIV PrEP Upstream Analysis
10.3 Long-Acting HIV PrEP Midstream Analysis
10.4 Long-Acting HIV PrEP Downstream Analysis

11 RESEARCH FINDINGS AND CONCLUSION

12 APPENDIX

12.1 Methodology
12.2 Research Process and Data Source
12.3 Disclaimer

+357 96 030922
info@marketpublishers.com

List Of Tables

LIST OF TABLES

Table 1. World Long-Acting HIV PrEP Revenue by Region (2021, 2025 and 2032) & (USD Million), (by Headquarter Location)
Table 2. World Long-Acting HIV PrEP Revenue by Region (2021-2026) & (USD Million), (by Headquarter Location)
Table 3. World Long-Acting HIV PrEP Revenue by Region (2027-2032) & (USD Million), (by Headquarter Location)
Table 4. World Long-Acting HIV PrEP Revenue Market Share by Region (2021-2026), (by Headquarter Location)
Table 5. World Long-Acting HIV PrEP Revenue Market Share by Region (2027-2032), (by Headquarter Location)
Table 6. Major Market Trends
Table 7. World Long-Acting HIV PrEP Consumption Value Growth Rate Forecast by Region (2021 & 2025 & 2032) & (USD Million)
Table 8. World Long-Acting HIV PrEP Consumption Value by Region (2021-2026) & (USD Million)
Table 9. World Long-Acting HIV PrEP Consumption Value Forecast by Region (2027-2032) & (USD Million)
Table 10. World Long-Acting HIV PrEP Revenue by Player (2021-2026) & (USD Million)
Table 11. Revenue Market Share of Key Long-Acting HIV PrEP Players in 2025
Table 12. World Long-Acting HIV PrEP Industry Rank of Major Player, Based on Revenue in 2025
Table 13. Global Long-Acting HIV PrEP Company Evaluation Quadrant
Table 14. Head Office of Key Long-Acting HIV PrEP Players
Table 15. Long-Acting HIV PrEP Market: Company Product Type Footprint
Table 16. Long-Acting HIV PrEP Market: Company Product Application Footprint
Table 17. Long-Acting HIV PrEP Mergers & Acquisitions Activity
Table 18. United States VS China Long-Acting HIV PrEP Revenue Comparison, (2021 & 2025 & 2032) & (USD Million)
Table 19. United States VS China Long-Acting HIV PrEP Consumption Value Comparison, (2021 & 2025 & 2032) & (USD Million)
Table 20. United States Based Long-Acting HIV PrEP Companies, Headquarters (States, Country)
Table 21. United States Based Companies Long-Acting HIV PrEP Revenue, (2021-2026) & (USD Million)
Table 22. United States Based Companies Long-Acting HIV PrEP Revenue Market

+357 96 030922
info@marketpublishers.com

Share (2021-2026)
Table 23. China Based Long-Acting HIV PrEP Companies, Headquarters (Province, Country)
Table 24. China Based Companies Long-Acting HIV PrEP Revenue, (2021-2026) & (USD Million)
Table 25. China Based Companies Long-Acting HIV PrEP Revenue Market Share (2021-2026)
Table 26. Rest of World Based Long-Acting HIV PrEP Companies, Headquarters (Province, Country)
Table 27. Rest of World Based Companies Long-Acting HIV PrEP Revenue (2021-2026) & (USD Million)
Table 28. Rest of World Based Companies Long-Acting HIV PrEP Revenue Market Share (2021-2026)
Table 29. World Long-Acting HIV PrEP Market Size by Type, (USD Million), 2021 & 2025 & 2032
Table 30. World Long-Acting HIV PrEP Market Size Value by Type (2021-2026) & (USD Million)
Table 31. World Long-Acting HIV PrEP Market Size by Type (2027-2032) & (USD Million)
Table 32. World Long-Acting HIV PrEP Market Size by Route of Administration, (USD Million), 2021 & 2025 & 2032
Table 33. World Long-Acting HIV PrEP Market Size Value by Route of Administration (2021-2026) & (USD Million)
Table 34. World Long-Acting HIV PrEP Market Size by Route of Administration (2027-2032) & (USD Million)
Table 35. World Long-Acting HIV PrEP Market Size by Time of Administration, (USD Million), 2021 & 2025 & 2032
Table 36. World Long-Acting HIV PrEP Market Size Value by Time of Administration (2021-2026) & (USD Million)
Table 37. World Long-Acting HIV PrEP Market Size by Time of Administration (2027-2032) & (USD Million)
Table 38. World Long-Acting HIV PrEP Market Size by Application, (USD Million), 2021 & 2025 & 2032
Table 39. World Long-Acting HIV PrEP Market Size by Application (2021-2026) & (USD Million)
Table 40. World Long-Acting HIV PrEP Market Size by Application (2027-2032) & (USD Million)
Table 41. Gilead Sciences Basic Information, Manufacturing Base and Competitors
Table 42. Gilead Sciences Major Business

+357 96 030922
info@marketpublishers.com

Table 43. Gilead Sciences Long-Acting HIV PrEP Product and Services
Table 44. Gilead Sciences Long-Acting HIV PrEP Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 45. Gilead Sciences Recent Developments/Updates
Table 46. Gilead Sciences Competitive Strengths & Weaknesses
Table 47. GSK Basic Information, Manufacturing Base and Competitors
Table 48. GSK Major Business
Table 49. GSK Long-Acting HIV PrEP Product and Services
Table 50. GSK Long-Acting HIV PrEP Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 51. GSK Recent Developments/Updates
Table 52. GSK Competitive Strengths & Weaknesses
Table 53. Global Key Players of Long-Acting HIV PrEP Upstream (Raw Materials)
Table 54. Global Long-Acting HIV PrEP Typical Customers

+357 96 030922
info@marketpublishers.com

List Of Figures

LIST OF FIGURES

Figure 1. Long-Acting HIV PrEP Picture
Figure 2. World Long-Acting HIV PrEP Total Revenue: 2021 & 2025 & 2032, (USD Million)
Figure 3. World Long-Acting HIV PrEP Total Revenue (2021-2032) & (USD Million)
Figure 4. World Long-Acting HIV PrEP Revenue by Region (2021, 2025 and 2032) & (USD Million), (by Headquarter Location)
Figure 5. World Long-Acting HIV PrEP Revenue Market Share by Region (2021-2032), (by Headquarter Location)
Figure 6. United States Based Company Long-Acting HIV PrEP Revenue (2021-2032) & (USD Million)
Figure 7. China Based Company Long-Acting HIV PrEP Revenue (2021-2032) & (USD Million)
Figure 8. Europe Based Company Long-Acting HIV PrEP Revenue (2021-2032) & (USD Million)
Figure 9. Japan Based Company Long-Acting HIV PrEP Revenue (2021-2032) & (USD Million)
Figure 10. South Korea Based Company Long-Acting HIV PrEP Revenue (2021-2032) & (USD Million)
Figure 11. ASEAN Based Company Long-Acting HIV PrEP Revenue (2021-2032) & (USD Million)
Figure 12. India Based Company Long-Acting HIV PrEP Revenue (2021-2032) & (USD Million)
Figure 13. Long-Acting HIV PrEP Market Drivers
Figure 14. Factors Affecting Demand
Figure 15. World Long-Acting HIV PrEP Consumption Value (2021-2032) & (USD Million)
Figure 16. World Long-Acting HIV PrEP Consumption Value Market Share by Region (2021-2032)
Figure 17. United States Long-Acting HIV PrEP Consumption Value (2021-2032) & (USD Million)
Figure 18. China Long-Acting HIV PrEP Consumption Value (2021-2032) & (USD Million)
Figure 19. Europe Long-Acting HIV PrEP Consumption Value (2021-2032) & (USD Million)
Figure 20. Japan Long-Acting HIV PrEP Consumption Value (2021-2032) & (USD

+357 96 030922
info@marketpublishers.com

Million)
Figure 21. South Korea Long-Acting HIV PrEP Consumption Value (2021-2032) & (USD Million)
Figure 22. ASEAN Long-Acting HIV PrEP Consumption Value (2021-2032) & (USD Million)
Figure 23. India Long-Acting HIV PrEP Consumption Value (2021-2032) & (USD Million)
Figure 24. Producer Shipments of Long-Acting HIV PrEP by Player Revenue ($MM) and Market Share (%): 2025
Figure 25. Global Four-firm Concentration Ratios (CR4) for Long-Acting HIV PrEP Markets in 2025
Figure 26. Global Four-firm Concentration Ratios (CR8) for Long-Acting HIV PrEP Markets in 2025
Figure 27. United States VS China: Long-Acting HIV PrEP Revenue Market Share Comparison (2021 & 2025 & 2032)
Figure 28. United States VS China: Long-Acting HIV PrEP Consumption Value Market Share Comparison (2021 & 2025 & 2032)
Figure 29. World Long-Acting HIV PrEP Market Size by Type, (USD Million), 2021 & 2025 & 2032
Figure 30. World Long-Acting HIV PrEP Market Size Market Share by Type in 2025
Figure 31. Cabotegravir Long-Acting PrEP
Figure 32. Lenacapavir Long-Acting PrEP
Figure 33. World Long-Acting HIV PrEP Market Size Market Share by Type (2021-2032)
Figure 34. World Long-Acting HIV PrEP Market Size by Route of Administration, (USD Million), 2021 & 2025 & 2032
Figure 35. World Long-Acting HIV PrEP Market Size Market Share by Route of Administration in 2025
Figure 36. Intramuscular Injectable PrEP
Figure 37. Subcutaneous Injectable PrEP
Figure 38. World Long-Acting HIV PrEP Market Size Market Share by Route of Administration (2021-2032)
Figure 39. World Long-Acting HIV PrEP Market Size by Time of Administration, (USD Million), 2021 & 2025 & 2032
Figure 40. World Long-Acting HIV PrEP Market Size Market Share by Time of Administration in 2025
Figure 41. Every 2 Months
Figure 42. Every 6 Months
Figure 43. World Long-Acting HIV PrEP Market Size Market Share by Time of Administration (2021-2032)
Figure 44. World Long-Acting HIV PrEP Market Size by Application, (USD Million), 2021

+357 96 030922
info@marketpublishers.com

& 2025 & 2032
Figure 45. World Long-Acting HIV PrEP Market Size Market Share by Application in 2025
Figure 46. Hospitals and HIV Specialty Clinics
Figure 47. Sexual Health Clinics
Figure 48. Public Health PrEP Programs
Figure 49. World Long-Acting HIV PrEP Market Size Market Share by Application (2021-2032)
Figure 50. Long-Acting HIV PrEP Industrial Chain
Figure 51. Methodology
Figure 52. Research Process and Data Source

+357 96 030922
info@marketpublishers.com

I would like to order

Product name: Global Long-Acting HIV PrEP Supply, Demand and Key Producers, 2026-2032
Product link: https://marketpublishers.com/r/G381B4199C24EN.html
Price: US$ 4,480.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:
info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/G381B4199C24EN.html